Treating Blood Cancers: Recent Episodes
The Leukemia & Lymphoma Society
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN
Recorded on June 23, 2026
Stephen Ansell, MD, PhD
Division Chair, Hematology
Mayo Clinic
Rochester, MN
Join Dr. Stephen Ansell from Mayo Clinic for an in-depth discussion on Waldenström macroglobulinemia, focusing on the latest advances in diagnosis, treatment, and management. This episode explores clinical features, the importance of molecular markers in guiding diagnosis and treatment decisions, and current indications for initiating therapy. The discussion also addresses the management of IgM-related complications, emerging therapeutic approaches, and future directions in care. Listen to this exciting and informative episode today!Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Resources for Patients
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY
Recorded on June 2, 2026
Marina Kremyanskaya, MD, PhD
Associate Professor
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY
Join Dr. Marina Kremyanskaya from the Icahn School of Medicine at Mount Sinai in this expert discussion on mastocytosis, including an overview of the disease, key signs and symptoms, and current diagnostic criteria with a focus on relevant genetic mutations. She discusses recently approved therapies, emerging treatment approaches, and ongoing clinical trials that are shaping future treatment. The episode also covers approaches to managing complications, addressing treatment-related side effects, and delivering patient-centered care.Don’t miss this informative episode!Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Resources for Patients
Tara Gregory, MD, Colorado Blood Cancer Institute, Denver, CO and Jay Spiegel, MD, Sylvester Comprehensive Cancer Center, Miami, FL
Recorded on May 28, 2026
Tara Gregory, MD
President
Colorado Blood Cancer Institute
Denver, CO
Jay Spiegel, MD
Assistant Professor
Division of Transplant and Cellular Therapy
University of Miami Sylvester Comprehensive Cancer Center
Miami, FL
In this episode, Dr. Tara Gregory from the Colorado Blood Cancer Institute, and Dr. Jay Spiegel from the Sylvester Comprehensive Cancer Center discuss the evolving role of CAR T-cell therapy in lymphoma and myeloma. They provide a practical overview of CAR-T, including currently approved indications, importance of early referral, patient selection considerations, and strategies for engaging patients in treatment discussions. The conversation also covers key aspects of toxicity management and post-treatment monitoring, while addressing current limitations of CAR-T therapy and future directions that may further expand its role in patient care. Tune in today for this exciting episode!Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Resources for Patients
This episode is supported by Bristol Myers Squibb, Johnson & Johnson & Legend Biotech, and Kite, a Gilead Company.
Lori Muffly, MD, MS, Stanford Medicine, Stanford, CA
Recorded on May 12, 2026
Lori Muffly, MD, MS
Professor of Medicine
Division of Blood and Marrow Transplantation & Cellular Therapy
Stanford Medicine
Stanford, CA
In this episode, Dr. Lori Muffly from Stanford Medicine explores how hematopoietic stem cell transplantation (HSCT) continues to play a central role in care, even as cellular therapies evolve. She also discusses recent advances in overall survival and graft versus host disease as well as clinical trials. We also explore barriers to access, the importance of multidisciplinary teams, and resources to support patients and healthcare professionals. Join us for this insightful episode on the important role of HSCT today, and where it’s headed next.Mentioned on this episode:
- www.NMDP.org
- www.hematology.org
Additional Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Resources for Patients
Mayra Allen, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Recorded on April 23, 2026
Mayra Allen, PhD
Clinical Psychologist, Psycho-Oncology Service
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Join us for an insightful conversation with Mayra Allen, PhD, clinical psychologist at UCSF’s Helen Diller Family Comprehensive Cancer Center, as we explore actionable strategies for supporting couples, caregivers, and families navigating cancer care. This episode examines practical communication approaches, the evolving role of care partners, and ways to help families manage complex situations. The discussion also addresses important yet often overlooked topics, including changes in intimacy, the impact of cultural perspectives across the cancer journey, and resources to support clinicians in delivering whole person oncology care. Tune in to this thoughtful discussion today!Mentioned on this episode:
- Caregivers Action Network (CAN)
- Family Caregiver Alliance
- Women’s Cancer Resource Center
Additional Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Resources for Patients
David Sallman, MD, Moffitt Cancer Center, Tampa, FL
Recorded on April 9, 2026
David Sallman, MD
Associate Member, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL
In this exciting episode, Dr. David Sallman from Moffitt Cancer Center takes a deep dive into acute myeloid leukemia (AML) and the advances transforming patient care. The discussion spans newly approved therapies, including menin inhibitors, as well as promising approaches under investigation in clinical trials, and explores how these innovations are influencing treatment selection, transplantation, and the management of side effects and complications in today’s AML landscape. Tune in today for expert insight into what’s shaping the future of AML care.Additional Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Resources for Patients
This episode is supported by Kura Oncology, Inc.
Matthew Loscalzo, LCSW, APOS Fellow, City of Hope, Duarte, CA
Recorded on March 30, 2026
Matthew Loscalzo, LCSW, APOS Fellow
Founding Executive Director and Professor Emeritus of Supportive Care Medicine
and Professor of Population Sciences
City of Hope
Duarte, CA
In this episode, licensed clinical social worker Matthew Loscalzo explores how survivors and healthcare professionals often define “normal” differently after treatment. He discusses the emotional shifts that impact relationships, work, and future planning, and shares how healthcare professionals can support meaningful conversations and shared decision-making after treatment ends. Tune in to hear practical insights for supporting patients beyond treatment.Mentioned on this episode:
- Loss and Grief: Personal Stories of Doctors and Other Healthcare Professionals by Linda Klein, Matthew Loscalzo (Editor), Marshall Forstein (Editor)
Additional Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Resources for Patients
Amy Pierre, MSN, ANP-BC, Flatiron Health and Memorial Sloan Kettering, New York, NY and Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC
Recorded on March 10, 2026
Amy Pierre, MSN, ANP-BC
Senior Clinical Director, Research Oncology, Flatiron Health
Nurse Practitioner, Memorial Sloan Kettering Cancer Center
New York, NY
Peter Voorhees, MD
Director, Outreach for Hematologic Malignancies, Plasma Cells Disorder
Program, Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Charlotte, NC
Professor, Cancer Medicine
Wake Forest University School of Medicine
Winston-Salem, NC
In this episode, Dr. Peter Voorhees from the Levine Cancer Institute and Amy Pierre, MSN, RN, ANP BC from Flatiron Health and Memorial Sloan Kettering, break down the evolving landscape of myeloma, from early signs and diagnostic criteria to frontline therapy, transplant decisions, and T- cell redirecting therapies. They explore real world challenges in survivorship, treatment toxicity, and disparities in access to advanced therapies, offering practical insights to help care teams support patients more effectively. Tune in for an informative and forward looking discussion shaping the future of myeloma management.Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Resources for Patients
Matthew Kutny, MD, University of Alabama, Birmingham, AL, Julie Guillot, Pediatric AML parent, global advocate, and Blood Cancer United Volunteer, and Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC
Recorded on February 19, 2026
Matthew Kutny, MD
Professor of Pediatrics
Director, Leukemia, Lymphoma and Histiocytosis Program
Director, Pediatric Clinical Trials Office
Institutional Principal Investigator, Children’s Oncology Group (NCI NCTN)
Pediatric Hematology and Oncology
University of Alabama at Birmingham
Birmingham, AL
Julie Guillot
Pediatric AML parent, global advocate, and Blood Cancer United Volunteer
Kelly Laschinger, MSN, RN, CPNP, CPHON
Director, Clinical Trial Support Center
Blood Cancer United
Washington, DC
In this episode, Dr. Matthew Kutny from the University of Alabama, and Kelly Laschinger, CPNP and Julie Guillot from Blood Cancer United, break down what clinicians and families need to know about Expanded Access (EA), also known as Compassionate Use, in treating pediatric oncology patients. They clarify key terms, outline when EA should be considered, and walk through how the process works in real-world practice. Their conversation also addresses common barriers, from institutional requirements to sponsor approval, and highlights how pediatric care teams and advocates can work together to navigate them. Tune in for an informative and insightful conversation to help healthcare professionals better understand and utilize Expanded Access!Blood Cancer United Resources:
- Clinical Trial Support Center
- Information Resource Center
- Dare to Dream Project
- Pediatric Acute Leukemia Master Clinical Trial (PedAL)
Mentioned on this episode:
- Project Facilitate
This episode is supported by the Tom Reich Educational Endowment Fund.
Brad Kahl, MD, Siteman Cancer Center, St. Louis MO
Recorded on January 27, 2026
Brad Kahl, MD
Professor of Medicine
Division of Oncology, Department of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St. Louis, MO
In this episode, join Dr. Brad Kahl, Director of the Lymphoma Program at the Siteman Cancer Center in St. Louis, Missouri, as he delivers a concise and practical overview of chronic lymphocytic leukemia (CLL), from initial disease presentation to key diagnostic considerations. Dr. Kahl discusses the prognostic value of cytogenetic testing and its impact on treatment selection and reviews currently approved therapeutic options alongside notable updates from the latest American Society of Hematology (ASH) meeting. He also examines emerging agents and ongoing clinical trials that are shaping the future CLL treatment landscape. The conversation further explores strategies for managing side effects, addressing complications, and supporting patients and caregivers. Tune in for this timely and informative discussion!Additional Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Resources for Patients
Building Resilience: Burnout & Compassion Fatigue Tools for HCPs
Chelsey Winegar, LCSW, MBA, Intermountain Health, Murray, UT
… Building Resilience: Burnout & Compassion Fatigue Tools for HCPsRead More »
Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC
Recorded on December 18, 2025
Lore Gruenbaum, PhD
Chief Scientific Officer & Senior Vice President of Research
Blood Cancer United
Washington, DC
Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know!Additional Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Resources for Patients
Raymond Mailhot, MD, MPH, University of Miami, Miami, FL
Recorded on December 2, 2025
Raymond Mailhot, MD, MPH
Department of Radiation Oncology
University of Miami
Miami, FL
Join us with Dr. Raymond Mailhot from the University of Miami as we explore how social determinants of health shape patient experiences, treatment decisions, and outcomes. He discusses the importance of cultural competence in delivering equitable, patient-centered care and shares practical communication strategies to better engage patients and collaborate effectively. This episode offers actionable insights to strengthen relationships and improve overall care quality. Tune in today to gain practical strategies that will enhance your approach to patient-centered care and drive better outcomes!Additional Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Medical Debt Case Management Program for Patients
- Blood Cancer United Additional Resources for Patients
Paul J. Hampel, MD, Mayo Clinic, Rochester, MN
Recorded on November 4, 2025
Paul J. Hampel, MD
Assistant Professor of Medicine
Division of Hematology, Department of Medicine
Mayo Clinic
Rochester, MN
In this episode, Dr. Paul Hampel from Mayo Clinic Rochester takes a comprehensive look at hairy cell leukemia (HCL). He reviews the current diagnostic work-up, including immunophenotypic and molecular testing, and highlights key clinical features that distinguish HCL from related disorders. Dr. Hampel also discusses approved frontline therapies and evidence-based approaches for relapsed or refractory disease, with attention to infection risk and supportive care. The conversation explores emerging agents, novel combinations, and clinical trials shaping the next wave of HCL management. Join us for this expert discussion, offering practical insights to enhance care and outcomes for patients with HCL.
Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Recorded on October 23, 2025
Michael J. Mauro, MD
Director, Chronic Myeloid Leukemia Program
Professor of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
Tune in for this expert-led discussion with Dr. Michael Mauro from Memorial Sloan Kettering Cancer Center on the evolving management of chronic myeloid leukemia (CML) in the era of tyrosine kinase inhibitors (TKIs) and newly approved FDA therapies. Dr. Mauro explores how TKIs have transformed prognosis, key factors guiding initial therapy selection, and best practices for managing treatment-related side effects. He also shares updates on TKI discontinuation criteria, long-term monitoring, and a forward look at ongoing trials and emerging therapeutic advances shaping the future of CML care. Gain actionable insights to enhance patient outcomes today!
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA
Recorded on September 25, 2025
Rahul Banerjee, MD, FACP
Assistant Professor
Fred Hutchinson Cancer Center
Seattle, WA
In this episode, Dr. Rahul Banerjee from Fred Hutchinson Cancer Center in Seattle, WA, discusses the evolving role of measurable residual disease (MRD) in hematologic malignancies. He explores what MRD is, how assays are used and interpreted, and its impact across the disease continuum. The conversation also covers MRD’s role in clinical trials, how to effectively explain MRD to patients, practical considerations for testing in community settings, and key education resources for both healthcare professionals and patients. Tune in today to gain practical insights you can apply in your daily practice!This episode is supported by Adaptive Biotechnologies Corporation and Allogene Therapeutics.
Ann Collins, PA, Blood Cancer United, Washington, DC, Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC, Sarah K. Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA
Recorded on September 9, 2025
Ann Collins, PA
Project Leader, Pediatric Acute Leukemia Master Clinical Trial (PedAL)
Blood Cancer United
Washington, DC
Kelly Laschinger, MSN, RN, CPNP, CPHON
Director, Clinical Trial Support Center
Blood Cancer United
Washington, DC
Sarah K. Tasian, MD
Blood Cancer United PedAL Master Clinical Trial Lead
Associate Professor of Pediatrics, University of Pennsylvania School of Medicine
Chief of Hematologic Malignancies Program, Children’s Hospital of Philadelphia
Philadelphia, PA
Join us for our first episode as Blood Cancer United! In this episode, Dr. Sarah Tasian, from Children’s Hospital of Philadelphia, and Ann Collins and Kelly Laschinger, from Blood Cancer United, join us for an in-depth discussion on pediatric acute leukemias. The conversation delves into the latest therapies, treatment challenges, and the complex realities of long-term survivorship. We also explore the groundbreaking Blood Cancer United Pediatric Acute Leukemia Master Clinical Trial (PedAL), its bold vision, global collaboration, and unified approach to data collection. Valuable clinical trial resources and strategies to support patients, families, and healthcare professionals are also shared. Tune in today!
Catherine Lai, MD, MPH, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, PA
Recorded on June 27, 2025
Catherine Lai, MD, MPH
Associate Professor
Physician Leader, Leukemia Clinical Research Unit
University of Pennsylvania Perelman Center for Advanced Medicine
Philadelphia, PA
In this episode, Dr. Catherine Lai, from the University of Pennsylvania’s Perelman Center for Advanced Medicine, joins us to discuss the current landscape of adult acute lymphoblastic leukemia (ALL) treatment. She highlights recent advances in frontline and relapsed therapies, the critical role of measurable residual disease (MRD), and the use of immunotherapy and targeted treatments. Dr. Lai further explores transplant considerations, management of side effects, and tailored approaches for B-cell and T-cell ALL. She also emphasizes patient-centered care, including strategies for end-of-life discussions and shared decision-making. Tune in today for expert insights and practical takeaways on the evolving future of ALL care!
Uma Borate, MBBS, MS, The Ohio State University, Cleveland, OH
Recorded on May 27, 2025
Uma Borate, MBBS, MS
Associate Professor, Division of Hematology
Acute Leukemia Clinical Research Disease Group Leader
The Ohio State University
Cleveland, OH
What’s changing in acute myeloid leukemia (AML)? Join Dr. Uma Borate from The Ohio State University in Columbus, Ohio, as she dives into emerging breakthroughs in AML biology, including molecular drivers, menin inhibitors, and the challenges of developing bispecifics and CAR T-cell therapies. She also shares updates from the LLS Beat AML® Master Clinical Trial and ongoing clinical trials, and reflects on the evolving treatment landscape across age groups. Don’t miss this dynamic conversation packed with expertise and hope for the future of AML!
Aaron Gerds, MD, MS, Cleveland Clinic, Cleveland, OH
Recorded on May 13, 2025
Aaron Gerds, MD, MS
Associate Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University School of Medicine
Medical Director
Case Comprehensive Cancer Center Clinical Research Office
Cleveland, OH
In this episode, Dr. Aaron Gerds from the Cleveland Clinic explores the intricacies of Myeloproliferative Neoplasms (MPNs), from diagnosis and monitoring to treatment goals and the latest therapeutic advances. Dr. Gerds discusses emerging therapies, the significance of clinical trials, strategies for managing side effects and long-term effects, and valuable resources for healthcare professionals, patients, and families. Tune in today for expert insights on MPNs!This episode is supported by GSK plc and Karyopharm Therapeutics.
Tessa Faye Flores, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Recorded on April 24, 2025
Tessa Faye Flores, MD
Medical Director, Cancer Screening and Survivorship
Roswell Park Comprehensive Cancer Center
Buffalo, NY
We are pleased to celebrate the 100th episode of Treating Blood Cancers with Dr. Tessa Flores from Roswell Park Comprehensive Cancer Center in Buffalo, New York, as she shares insights into survivorship care. In this episode, Dr. Flores explores the different phases of survivorship and the psychosocial challenges that accompany each stage. She highlights the vital role of a collaborative care team, including primary care practitioners, in supporting survivors of cancer to achieve and maintain a healthy post-treatment life. As the number of survivors continues to grow, the focus on long-term wellness becomes increasingly important. Dr. Flores emphasizes, “A tenet of survivorship care is preventive care”. Tune in for this special episode and join the conversation today!This episode is supported by Genentech, A Member of the Roche Group.
Additional Episodes on Survivorship Care:
- Key Strategies for HCPs: Supporting Caregivers and Care Partners
- Understanding Mental Health in Cancer Survivorship
- Navigating Adult Survivorship Care
- Exploring Survivorship Needs of Older Adults
- Strategic Approaches to Pediatric and AYA Survivorship Care
- Creating a Roadmap for Adult Survivorship Care
- Survivorship Care of Older Adults: Addressing the Unique Needs
- Supporting Adolescent and Young Adult (AYA) Survivors
- A Conversation on Adult Survivorship
Mikkael A. Sekeres, MD, MS, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
Recorded on April 17, 2025
Mikkael A. Sekeres, MD, MS
Chief, Division of Hematology
Professor of Medicine
Sylvester Comprehensive Cancer Center
University of Miami
Miami, FL
Join us with Dr. Mikkael Sekeres of the University of Miami Sylvester Comprehensive Cancer Center as he explores the complexities of diagnosing and treating Myelodysplastic Syndromes (MDS), including “watch and wait.” Through case-based discussion, he highlights advances in high-risk MDS management, from novel targeted therapies to stem cell transplantation and clinical trials. Dr. Sekeres also shares strategies for managing side effects and emphasizes the importance of multidisciplinary care in improving patient outcomes. Tune in to gain valuable insights on MDS today!
Jeffrey Magee, MD, PhD, Washington University School of Medicine, St. Louis, MO
Recorded on April 3, 2025
Jeffrey Magee, MD, PhD
Elizabeth H. and James S. McDonnell III Professor of Pediatrics
Director, McDonnell Pediatric Cancer Center
Division of Pediatric Hematology and Oncology
Washington University School of Medicine
St. Louis, MO
In this episode, we sit down with Dr. Jeffrey Magee from the McDonald Pediatric Cancer Center at the Washington University School of Medicine in St. Louis to discuss the evolving landscape of pediatric blood cancers. Reflecting on his work, Dr. Magee shares, “One of the things I really love about the job is that it operates right at the interface between the science and the professional practice of medicine.” He examines groundbreaking advances bringing new hope to children and their families, from novel therapies and CAR T-cell therapy to the crucial role of clinical trials. Dr. Magee also speaks candidly about the challenges of delivering difficult news and shares compassionate strategies for supporting families through their toughest moments. Join us for this insightful and informative conversation on the future of pediatric blood cancer care today!Additional LLS Resource:
Stars Will Twinkle, The Sun Will Shine
A three-book series and movie for kids with blood cancer. Follow Olivia and her family as she is diagnosed with leukemia, goes to the hospital for treatment, and returns to school.
Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN
Recorded on March 18, 2025
Angela Dispenzieri, MD
Consultant, Division of Hematology
Serene M. and Frances C. Durling Professor of Medicine and of Laboratory
Medicine and Pathology
Mayo Clinic
Rochester, MN
Join us as we dive into in the complex care of amyloid and myeloma with Dr. Angela Dispenzieri from Mayo Clinic Rochester, Minnesota. She explains the diagnosis and explores the differences between amyloid and myeloma. Discussion on treatment strategies for complex cases, side effects of therapies, and difficult conversations with patients, provide practical information on patient care. Tune in today to learn more about the complexities of myeloma.This episode is supported by GSK plc.
Guy Maytal, MD, Forge Health and Weill Cornell Medicine, New York
Recorded on February 20, 2025
Guy Maytal, MD
Chief Medical Officer, Forge Health
White Plains, NY
Clinical Assistant Professor of Psychiatry, Weill Cornell Medicine
New York, NY
In this episode, Dr. Guy Maytal, from Forge Health and Weill Cornell Medicine in New York, explores burnout and wellness in healthcare professionals, highlighting the difference between burnout and compassion fatigue. He shares valuable insights on recognizing these issues, while emphasizing the importance of connection, resilience, and self-care in preventing and overcoming burnout. Dr. Maytal also offers practical strategies for institutions to better support healthcare professionals. Tune in for the latest insights on healthcare professional wellness today!
Timothy Pearman, PhD, ABPP, Northwestern University Feinberg School of Medicine, Chicago, IL Recorded on February 6, 2025 Timothy Pearman, PhD, ABPP Director, Supportive Oncology Robert H. Lurie Comprehensive Cancer Center Professor, Department of Medical Social Sciences and Psychiatry & Behavioral Sciences Northwestern University Feinberg School of Medicine Chicago, IL Join us for an insightful episode […]
Jason Westin, M.D., MS, FACP, MD Anderson Cancer Center, Houston, TX Recorded on January 21, 2025 Jason Westin, M.D., MS, FACP Professor, Department of Lymphoma & Myeloma Lead, Lymphoma & Myeloma Service Line Director, Lymphoma Clinical Research Section Chief, Aggressive and Indolent Lymphoma MD Anderson Cancer Center Houston, TX In this episode, Dr. Jason Westin […]
Jaehyuk (Jae) Choi, MD, Northwestern University Feinberg School of Medicine, Chicago, IL Recorded on January 7, 2025 Jaehyuk (Jae) Choi, MD Jack W. Graffin Associate Professor of Dermatology and of Biochemistry and Molecular Genetics Northwestern University Feinberg School of Medicine Chicago, IL In this episode, Dr. Jaehyuk Choi from Northwestern University, explores Cutaneous T-Cell Lymphoma […]
Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 19, 2024 Lee Greenberger, PhD Chief Scientific Officer and SVP The Leukemia & Lymphoma Society Rye Brook, NY In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to provide information […]
Celeste Bello, MD, Moffitt Cancer Center, Tampa, FL Recorded on November 21, 2024 Celeste Bello, MD Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL Join us as we dive into bispecific antibodies with Dr. Celeste Bello from Moffitt Cancer Center, exploring their mechanisms of action, current indications in lymphoma, and strategies for […]
Understanding Mental Health in Cancer Survivorship Lynn Gooden, BSN, RN, ONN-CG, Community Health Network MD Anderson Cancer Center, Indianapolis, IN and Cassie Osborne, MSN, RN, OCN, ONN-CG, Community Health Network MD Anderson Cancer Center, Indianapolis, IN Recorded on November 14, 2024 Lynn Gooden, BSN, RN, ONN-CG Oncology Navigation and Survivorship Manager Oncology Navigation Community Health […]
Kerry A. Rogers, MD, The Ohio State University, Columbus, OH Recorded on October 29, 2024 Kerry A. Rogers, MD Associate Professor Division of Hematology The Ohio State University Columbus, OH Tune in for this comprehensive overview of Chronic Lymphocytic Leukemia (CLL) with Dr. Kerry Rogers from The Ohio State University. She covers key risk factors, […]
Jennifer R. Rushton, MD, Clinical Pathology Associates and the Baptist Health System, San Antonio, TX and Eric Severson, MD, PhD, Labcorp Oncology, Shelton, CT Recorded on July 2, 2024 Join us, as we dive into the crucial topic of biomarker testing with Dr. Jennifer Rushton from Clinical Pathology Associates and the Baptist Health System, and […]
Stacie B. Dusetzina, PhD, Vanderbilt University Medical Center, Nashville, TN and Bethany Lilly, JD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on September 20, 2024 Tune in to this informative episode as Dr. Stacie Dusetzina from Vanderbilt University and Bethany Lilly from The Leukemia & Lymphoma Society’s Office of Public Policy simplify the […]
Alex F. Herrera, MD, City of Hope Medical Center, Duarte, CA Recorded on June 27, 2024 Alex F. Herrera, MD Associate Professor Chief, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation Associate Medical Director, Briskin Center for Clinical Research & City of Hope Duarte Clinical Trials Office City of Hope Medical Center Duarte, […]
Shira Dinner, MD, Northwestern University, Chicago, IL and Tom Martin, MD, University of California San Francisco, San Francisco, CA Recorded on September 9, 2024 Join us for this special episode, recorded at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, TX! Guest host and conference attendee, Lauren Berger, Senior Director of […]
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA Recorded on June 6, 2024 Krish Patel, MD Director, Lymphoma Program Director, Hematologic Malignancies and Cellular Therapy Swedish Cancer Institute Seattle, WA Join us as Dr. Krish Patel from Swedish Cancer Institute explores mantle cell lymphoma, including the goals and latest advancements in treatment. He also provides […]
Ximena Jordan-Bruno, MD, University of Pennsylvania, Philadelphia, PA Recorded on June 4, 2024 Ximena Jordan-Bruno, MD Assistant Professor, Division of Hematology/Oncology University of Pennsylvania Philadelphia, PA Join us for this fascinating episode, where Dr. Ximena Jordan-Bruno from the University of Pennsylvania explores hereditary myeloid and hematologic disorders, covering their classifications, mutations, and related germline predisposition […]
Susan Hong, MD, Virginia Commonwealth University, Richmond, VA Recorded on May 21, 2024 Susan Hong, MD Director, Cancer Survivorship Program, Massey Comprehensive Cancer Center Associate Professor, School of Medicine Internal Medicine Virginia Commonwealth University Richmond, VA Tune in as Dr. Susan Hong, Cancer Survivorship Program Director at Virginia Commonwealth University’s Massey Cancer Center, discusses survivorship […]
David Dean, DDS, MSD, DABOM, FDS RCSEd, Fred Hutchinson Cancer Center and University of Washington School of Dentistry, Seattle, WA Recorded on April 25, 2024 David Dean, DDS, MSD, DABOM, FDS RCSEd Director, Oral Medicine Fred Hutchinson Cancer Center Clinical Associate Professor University of Washington School of Dentistry Seattle, WA Join us, as Dr. David […]
Cesar Rodriguez, MD, Mount Sinai Hospital, New York, NY
Recorded on April 16, 2024
Cesar Rodriguez, MD
Associate Professor of Medicine, Tisch Cancer Institute
Clinical Director, Multiple Myeloma Center of Excellence
Mount Sinai Hospital
New York, NY Join us for an insightful episode with Dr. Cesar Rodriguez from Mount Sinai Hospital as he discusses the healthcare provider’s role in survivorship care for older adults. Dr. Rodriguez explores the unique challenges of managing long-term and late effects of treatment and coordinating follow-up care. He also shares valuable perspectives on the impact of language and cultural considerations, along with the importance of caregiver support for older adult survivors. Listen in today!This episode is supported by Genentech, Inc. & Biogen and Merck & Co., Inc.
Karen E. Effinger, MD, MS, Children’s Healthcare of Atlanta, Atlanta, GA
Recorded on April 4, 2024
Karen E. Effinger, MD, MS
Associate Professor of Pediatrics
Emory University School of Medicine
Co-Director, Survivor Program
Aflac Cancer & Blood Disorders Center, Children’s Healthcare of Atlanta
Atlanta, GA In this episode, Dr. Karen Effinger from Children’s Healthcare of Atlanta, provides a comprehensive overview into survivorship care for pediatric, adolescent, and young adult (AYA) patients. Dr. Effinger discusses long-term effects of treatment, importance of survivorship guidelines, survivorship care plans, and ongoing care management. She also addresses approaches to support survivors and their families to underscore the vital role in optimizing outcomes. Tune in today to hear valuable insights into supporting pediatric and AYA survivors!This episode is supported by Genentech, Inc. & Biogen and Merck & Co., Inc.
Hagop M. Kantarjian, M.D., MD Anderson Cancer Center, Houston, TX
Recorded on March 28, 2024
Hagop M. Kantarjian, M.D.
Professor and Chairman, Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
MD Anderson Cancer Center, University of Texas
Houston, TX Join us for this episode as Dr. Hagop Kantarjian from MD Anderson Cancer Center discusses the latest advancements and progress in treating Acute Myeloid Leukemia (AML). From understanding genetic mutations to exploring emerging treatment options, Dr. Kantarjian shares valuable insights into the forefront of AML research and care.Learn more today!
Michael Tees, MD, MPH, Colorado Blood Cancer Institute, Denver, CO
Recorded on March 12, 2024
Michael Tees, MD, MPH
Director, Lymphoma Program
Lymphoma Executive Committee Member, Sarah Cannon Research Institute
Associate Member, Colorado Blood Cancer Institute
Denver, CO Join Dr. Michael Tees from the Colorado Blood Cancer Institute, as he discusses Chimeric antigen receptor (CAR) T-cell therapy in 2024. Dr. Tees provides an overview of immunotherapy and approved indications, how to discuss treatment options with your patients, what to consider when referring patients for CAR T-cell therapy, how to prepare patients, and educating patients and caregivers about toxicity management. He also provides insight into the limitations of CAR-T therapy, as well as future directions. Tune in to this informative episode today to learn more!This episode is supported by Bristol Myers Squibb, Johnson & Johnson|Legend Biotech, Kite, a Gilead Company, and Novartis Pharmaceuticals Corporation.
Alfred Lee, MD, PhD, Yale University, New Haven, CT
Recorded on February 22, 2024
Alfred Lee, MD, PhD
Professor of Medicine, Yale School of Medicine
Program Director, Hematology and Medical Oncology Fellowship
Chief, Division of Classical Hematology, Yale Cancer Center
Yale University
New Haven, CT Join us for this important and engaging episode, as Dr. Alfred Lee from Yale University addresses stress and burnout in healthcare professionals. While reflecting on his personal experience, Dr. Lee discusses warning signs, symptoms, risk factors, and strategies and resources to help reduce and prevent burnout. Tune in today!
Meghna Ailawadhi, M.B.B.S., M.D., Mayo Clinic, Jacksonville, FL
Recorded on December 7, 2023
Meghna Ailawadhi, M.B.B.S., M.D.
Cancer Survivorship Consultant, Assistant Professor of Medicine
Department of Hematology/Oncology
Mayo Clinic
Jacksonville, FL In this episode, Dr. Meghna Ailawadhi from the Mayo Clinic in Jacksonville, FL joins us for a conversation on survivorship care for adults. Dr. Ailawadhi discusses the importance of shared decision-making and coordination with primary care, including strategies to support adherence. She also provides an overview of disparities and challenges in survivorship care, as well as education and support resources for healthcare professionals and survivors. Learn more by listening today!This episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Merck & Co. Inc.
Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY
Recorded on December 19, 2023
Lee Greenberger, PhD
Chief Scientific Officer and SVP
The Leukemia & Lymphoma Society
Rye Brook, NY Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to discuss highlights from the 65th American Society of Hematology (ASH) Annual Meeting in December 2023, including updates on blood cancer research, treatment, and clinical trials in leukemia, lymphoma, myeloma, MDS, and MPNs. Tune in to this informative update today!
Jeffery Auletta, MD, National Marrow Donor Program® (NMDP)/Be the Match®Recorded on November 30, 2023
Jeffery Auletta, MD
Senior Vice President, Patient Outcomes and Experience
National Marrow Donor Program® (NMDP)/Be The Match®
Chief Scientific Director
CIBMTR® (Center for International Blood and Marrow Transplant Research®)
National Marrow Donor Program® (NMDP)/Be The Match® Join us as Dr. Jeffery Auletta from the National Marrow Donor Program® (NMDP)/Be the Match® reflects on the history, advances, and future of transplantation to treat blood cancers. Dr. Auletta also shares insights on disparities and barriers to receiving a transplant, expanding access, and how healthcare professionals can support patients through transplantation. Tune in to this engaging episode today!
Jacqueline Barrientos, MD, MS, Laura Ortiz-Ravick, MA, Kristina Lopez, LCSWRecorded on November 3, 2023
| | Jacqueline Barrientos, MD, MS Chief of Hematologic MalignanciesDirector of Oncology ResearchMount Sinai Medical CenterAdjunct Professor of Medicine Zucker School of Medicine at Hofstra/Northwell Miami Beach, FL | | | Laura Ortiz-Ravick, MADirector, Outreach and Health Promotion The Leukemia & Lymphoma Society Rye Brook, NY | | | Kristina Lopez, LCSWInformation Specialist The Leukemia & Lymphoma Society Rye Brook, NY |
Join us for this special episode, recorded live from the Florida Society of Clinical Oncology Annual Disparities in Cancer Care Summit. Guest host, Kristina Lopez, LCSW and Information Specialist at The Leukemia & Lymphoma Society, speaks with Dr. Jacqueline Barrientos from Mount Sinai Medical Center, and Laura Ortiz-Ravick, Director of Outreach and Health Promotion at The Leukemia & Lymphoma Society about barriers and disparities within the Hispanic and Latinx communities when navigating the cancer journey. Learn more by tuning in here!
Frank Penedo, Ph.D, University of Miami, Miami, FLRecorded on August 10, 2023
Frank Penedo, Ph.D
Professor, Departments of Psychology and Medicine
Associate Director for Cancer Survivorship and Translational Behavioral Sciences
University of Miami Sylvester Comprehensive Cancer Center
Sylvester DCC Endowed Chair in Cancer Survivorship
University of Miami
Miami, FL Tune in as we’re joined by Dr. Frank Penedo from the University of Miami for an important discussion on considerations in survivorship care of older adults. Dr. Penedo outlines long-term and late effects of treatment, including psychosocial implications, and the impact of culture and language on survivorship. He also shares strategies for follow-up care coordination, as well as communicating with survivors and their families. Be part of the conversation today!
This episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Merck & Co. Inc.
John Salsman, Ph.D, Wake Forest University School of Medicine, Winston-Salem, NCRecorded on June 22, 2023
John Salsman, Ph.D
Director, Clinical Research in Adolescent and Young Adult (AYA) Oncology
Co-Leader, Cancer Prevention and Control Program at the Atrium Health Wake
Forest Baptist Comprehensive Cancer Center
Professor, Department of Social Sciences and Health Policy at the Wake Forest
University School of Medicine
Winston-Salem, NC In this episode, Dr. John Salsman from Wake Forest University School of Medicine joins special staff correspondent, Elissa Baldwin, to discuss quality of life in the cancer experience of adolescents and young adults (AYAs), including unique issues that AYAs face. Dr. Salsman offers approaches to questions healthcare providers can ask when communicating with AYAs and clinical resources for physicians and survivors. Tune in today!
Tung Wynn, MD, University of Florida, Gainesville, FL and Braulio HernandezRecorded on June 10, 2023
Join Dr. Tung Wynn from the University of Florida, and Braulio Hernandez, a childhood cancer advocate and AYA survivor of Hodgkin Lymphoma, as they discuss the unique experiences of adolescents and young adults from active treatment to survivorship. Dr. Wynn and Braulio reflect on the physical and psychosocial long-term and late effects of treatment, strategies to support survivors and their families, survivorship guidelines, follow-up care coordination, and resources for clinical staff and for survivors. Listen to this engaging conversation today!
| | Tung Wynn, MD Director, Pediatric Cancer Survivorship Program Associate Professor of Pediatrics Division of Pediatric Hematology and Oncology University of FloridaGainesville, FL | | | Braulio HernandezChildhood Cancer Advocate AYA Survivor of Hodgkin Lymphoma |
This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Merck & Co. Inc., Pharmacyclics LLC, An AbbVie Company & Janssen Biotech, Inc.**
Chasity Burrows Walters, PhD, RN, Memorial Sloan Kettering Cancer Center, New York, NY
Recorded on April 13, 2023
Chasity Burrows Walters, PhD, RN
Vice President, Educational, Clinical, & Patient Communication
Memorial Sloan Kettering Cancer Center
New York, NY In this important conversation, Dr. Chasity Burrows Walters from Memorial Sloan Kettering Cancer Center discusses the barriers that persons within the LGBTQI+ community experience in accessing healthcare and the impact of discrimination on health outcomes. Dr. Burrows Walters offers guidance to help healthcare providers foster a respectful and sensitive environment for patients and their caregivers, including use of pronouns, gender-inclusive language, cancer screening guidelines, and resources for clinical staff and for patients. Learn more by tuning in today!
Ehab Atallah, MD, Medical College of Wisconsin, Milwaukee, WI
Recorded on January 24, 2023
Ehab Atallah, MD
Professor of Medicine
Associate Director, Cancer Service Line
Section Head, Hematologic Malignancies
Division of Hematology and Oncology
Medical College of Wisconsiny
Milwaukee, WI In this episode, Dr. Ken Miller sits down with Dr. Ehab Atallah, from the Medical College of Wisconsin, to discuss chronic myeloid leukemia (CML) including the development of tyrosine kinase inhibitors (TKIs), challenges with adherence to treatment, side effect management, and long-term and late effects, including cardiac toxicities. Dr. Atallah describes the work of the H. Jean Khoury Cure CML Consortium, shares his insights in to transitioning patients off TKIs, experience with his patients living with measurable residual disease, and excitement about the future of CML therapy. Learn more by tuning in today!
Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY
Recorded on December 19, 2022
Lee Greenberger, PhD
Chief Scientific Officer and SVP
The Leukemia & Lymphoma Society
Rye Brook, NY In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to provide an update on the information presented at the 64th American Society of Hematology (ASH) Annual Meeting, including leukemia, lymphoma, myeloma, MDS, and MPNs. Dr. Greenberger discusses updates in blood cancer therapies, including CAR T-cell therapy, bi-specific antibodies, and vaccine therapy, reviews the latest data on COVID-19, and addresses challenges that exist in diversity and equity in the healthcare system, including ways to overcome these barriers. Tune in today!
Shayna Sarosiek, MD, Dana Farber Cancer Institute, Boston, MA
Recorded on December 6, 2022
Shayna Sarosiek, MD
Assistant Professor
Harvard Medical School
Dana Farber Cancer Institute
Boston, MA Waldenström Macroglobulinemia (WM) is a rare blood cell cancer characterized by an excess number of abnormal white blood cells in the bone marrow. How does WM fit into the spectrum of other blood cancer diseases? Who is at risk? What are the genetic factors? Dr. Shayna Sarosiek, from the Dana-Farber Cancer Institute, joins us to provide a deep dive into WM, including testing, monitoring, treatment updates, clinical trials, and so much more. Tune in today! This activity is developed through a collaboration with the International Waldenström’s Macroglobulinemia Foundation.
Sattva S. Neelapu, MD, M.D. Anderson Cancer Center, Houston, TX
Recorded on December 16, 2022
Sattva S. Neelapu, MD
Professor and Deputy Chair
Department of Lymphoma and Myeloma
The University of Texas M.D. Anderson Cancer Center
Houston, TX Chimeric antigen receptor (CAR) T-cell therapy has generated impressive results in hematologic malignancies, with many drugs still in clinical trials. In this episode, Dr. Sattva S. Neelapu from MD Anderson Cancer Center, joins us to discuss updates on CAR T-cell therapy from the 2022 American Society of Hematology (ASH) Annual Meeting. Dr. Neelapu also provides a high-level overview of how CAR T-cell therapy works, including the manufacturing process, and discusses the risk of recurrence following therapy, risk for patients in the era of COVID-19, secondary cancers, associated costs, roadblocks to therapy, and why early referral matters. Tune in to this informative podcast episode to learn more!This podcast episode is supported by Allogene Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Janssen Oncology & Legend Biotech, Kite, A Gilead Company and Novartis Oncology.
Daphne Friedman, MD, Durham VA Health Care System, Durham, NC Recorded on October 20, 2022 In Part II of Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia, Dr. Daphne Friedman, from the Durham VA Health Care System in North Carolina, discusses the importance of a relationship between the provider and the patient when it comes to shared decision making (SDM), including the unique conversations of SDM with young adults and with healthcare providers who are patients. Dr. Friedman also shares challenges with seeking a second opinion, relying on information found on the internet, and additional resources. Tune in today to learn more! This podcast episode is supported by AbbVie Inc. and Genentech, Inc.
Eytan M. Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on October 7, 2022 Dr. Eytan Stein, from Memorial Sloan Kettering Cancer Center, joins us to reflect on breakthroughs in acute myeloid leukemia, including updates in treatment, long-term and late effects of therapy, and side effect management. Tune in to this episode as Dr. Stein discusses an overview of data presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) as well as updates from The Leukemia & Lymphoma Society’s BEAT AML® Master Trial.
Saad Z. Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on September 30, 2022 Join us for this special episode, recorded live from the Tenth Annual Meeting of the Society of Hematologic Oncology in Houston, TX! Guest host and conference attendee, Lauren Berger, Senior Director of Professional Education and Engagement at The Leukemia & Lymphoma Society, speaks with Dr. Saad Usmani, from Memorial Sloan Kettering Cancer Center, about his insights into the progress in immunotherapies in blood cancers shared at the conference. Not able to attend SOHO? Learn more about what was shared at the conference by tuning in here!
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX Recorded on September 6, 2022 Join us as Dr. Naveen Pemmaraju from MD Anderson Cancer Center, returns to discuss blastic plasmacytoid dendritic cell neoplasms (BPDCN)! In this episode, Dr. Pemmaraju provides an overview of BPDCN, including major updates in the treatment of the disease since our last episode on this topic in 2019. What is BPDCN? How is it treated? Is it curable? What resources are available for patients living with this rare disease? Join the conversation and learn more today! This podcast episode is supported by Stemline Therapeutics, Inc.
Jason Gotlib, MD, Stanford University School of Medicine, Palo Alto, CA Recorded on July 19, 2022 Mastocytosis is a rare and complex disease. In this special episode, Dr. Jason Gotlib from the Stanford University School of Medicine in Palo Alto, CA, discusses an overview of the disease, including its subtypes, clinical presentations, and treatment related toxicities. Dr. Gotlib addresses the importance of second opinions, collaborating with multidisciplinary specialists to treat patients, unmet needs and exciting new and emerging treatments. Learn more about the future of mastocytosis by listening to this episode today! This podcast episode is supported by Blueprint Medicines Corporation.
Rafael Fonseca, MD, Getz Family Professor of Cancer, Phoenix, AZ Recorded on June 30, 2022 In this episode, Dr. Rafael Fonseca, from the Mayo Clinic in Arizona, joins Dr. Ken Miller to breakdown the complex and complicated nature of genomics and molecular profiling. He discusses the role of molecular profiling in treating blood cancers, explains how we integrate genomics into the standard of care for people living with cancer, the potential of false negatives, provides examples of clinical applications, financial implications, and resources for patients. Tune in to the conversation today! This podcast episode is supported by Blueprint Medicines Corporation.
Kevin C. Oeffinger, MD, FASCO, Duke University Medical Center, Durham, NC Recorded on June 9, 2022 Children diagnosed with cancer are a heterogenous population experiencing different cancer diagnoses and therapies. Each journey presents its own physical, emotional, and psychosocial challenges that healthcare providers need to be attentive to. In this episode, Dr. Kevin Oeffinger, from Duke University in Durham, North Carolina, joins us to discuss the history of pediatric survivorship, physical, long-term, and late effects of treatment, including fertility considerations, strategies to support the survivor through psychosocial and cognitive effects, following a survivorship care plan, symptom monitoring, follow-up care, and so much more. Tune in to this important conversation today! This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Pharmacyclics LLC, An AbbVie Company and Janssen Biotech, Inc.
Gwen L. Nichols, MD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on May 20, 2022 Through the LLS Children’s Initiative, The Leukemia & Lymphoma Society (LLS) is setting out to fundamentally change how children with blood cancer are treated and cared for. For children and their families, LLS provides free education, support services, financial assistance, advocacy efforts, and has increased its research investments in childhood blood cancer. As part of this initiative, LLS PedAL, a first-of-its-kind global master clinical trial for pediatric acute leukemia patients, will fundamentally change how children are treated. In this episode, Dr. Gwen Nichols, EVP and Chief Medical Officer joins us to discuss PedAL, including sharing reflections on lack of pediatric ALL and AML therapies that led to the development of this master clinical trial. Dr. Nichols discusses challenges in creating pediatric therapies, the importance of data collection and creating a standard of care, and the ultimate impact PedAL will have on all clinical trials moving forward. Tune in today!
Zalman Suldan, MD, PhD, Hackensack University Medical Center – Hackensack Meridian Health, Hackensack, NJ Recorded on May 3, 2022 The primary care physician plays an important role in the treatment of patients living with a chronic blood disorder, from early diagnosis to appropriate referral to a hematologist-oncologist, from coordination of care to goals of therapy. In this episode, we are joined by Dr. Zalman Suldan, from Hackensack Medical Center in New Jersey, who shares his unique insights as both a primary care physician and nephrologist. Tune in today! This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.
Rayne H. Rouce, MD, BS, Texas Children’s Cancer Center for Cell and Gene Therapy, Houston, TX Recorded on April 8, 2022 As CAR T-cell therapy continues to evolve in new and exciting ways, new indications are approved and treatment toxicities reduced. In this episode, Dr. Rayne Rouce, from the Texas Children’s Cancer Center for Cell and Gene Therapy at Baylor College in Houston, joins us to discuss hot topics in CAR T-cell therapy, including how CAR-T has evolved over the past few years, understanding why some patients do better than others, access to treatment and overcoming logistics, shared care models with the referring physician, CAR-T in pediatric patients, communicating with patients, and so much more! This podcast episode is supported by Bristol Myers Squibb, CRISPR Therapeutics, Kite, a Gilead Company, Janssen Oncology & Legend Biotech, and Novartis Pharmaceuticals Corporation.
Francine Foss, MD and John A. Zic, MD, MMHC Recorded on March 28, 2022 This informative episode covers everything you need to know about cutaneous T-cell lymphoma, from its biology, subclassifications, targeted therapy, goals of treatment, novel toxicities, and so much more! Join Dr. Ken Miller as he delves into cutaneous T-cell lymphoma with two special guests; Dr. Francine Foss from Yale University School of Medicine and Dr. John Zic from Vanderbilt University Medical Center. Learn more about cutaneous T-cell lymphoma from a 60,000 foot view, disparities in the delivery of care, and exciting new research presented at the United States Cutaneous Lymphoma Consortium Annual Meeting. Tune in today!
Srdan Verstovsek, MD, PhD, MD Anderson Cancer Center, Houston, TX Recorded on February 18, 2022 In this month’s episode, Dr. Srdan Verstovsek, from MD Anderson Cancer Center in Houston, Texas, joins us to discuss myelofibrosis. What is myelofibrosis? What is our understanding of the disease? What are the deciding factors for cells to branch off into myelofibrosis and not other myeloproliferative neoplasms? Tune in as we explore myelofibrosis, including discussion on diagnosing and staging, goals and considerations for therapy, the impact of COVID-19 on treatment, and new and emerging drugs in development. This podcast episode is supported by AbbVie Inc.
Jacqueline C. Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY Recorded on February 1, 2022 Shared decision making between patients and their healthcare team is an important component to treatment, regardless of the diagnosis. For chronic leukemias, patient worries may be intensified when doctors suggest forgoing active treatment for a watch-and-wait approach. In this episode, Dr. Jacqueline Barrientos, from the Northwell Health Cancer Institute in Lake Success, New York, highlights the importance of shared decision making with her patients. Dr. Barrientos discusses challenges that arise, shared decision making across the multidisciplinary team, navigating second opinions, long-term and late effects, and maintaining open lines of communication. Listen in on this important conversation today! This podcast episode is supported by AbbVie Inc. and Genentech, Inc.
Caron Jacobson, MD, Dana-Farber Cancer Institute, Boston, MA Recorded on January 4, 2022 As we move into 2022, chimeric antigen receptor (CAR) T-cell therapy continues to be a very exciting and effective treatment option for some blood cancer patients. In this episode, Dr. Caron Jacobson, Assistant Professor of Medicine, Harvard Medical School, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute in Boston, MA, discusses updates in CAR T-cell therapy, including progress in managing toxicities, barriers to treatment, CAR T structure and manufacturing, other practical issues such as determining the best treatment option for patients facing serious disease, and future directions. Tune in to learn more! This podcast episode is supported by Bristol Myers Squibb; CRISPR Therapeutics; Kite, a Gilead Company and Novartis Pharmaceuticals Corporation.
Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 22, 2021 Each year, blood cancer professionals gather at the American Society of Hematology Annual Meeting to discuss the latest updates in blood cancer research, treatment, and clinical trials. In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, highlights the inflection points from the 63rd ASH Annual Meeting, including CAR T-cell therapy, bi-specific antibodies, and cell-free DNA. He reviews the latest data on Covid-19 and effectiveness of vaccinations in the blood cancer patient population. Tune in to this informative update today!
John P. Leonard, MD, Weill Cornell Medicine, New York Presbyterian, New York, NY Recorded on December 16, 2021 As 2021 comes to a close, the COVID-19 pandemic continues to evolve. In this episode, Dr. John Leonard, from Weill Cornell Medicine, New York Presbyterian Hospital, discusses the latest updates on how COVID-19 affects the blood cancer patient population. What is the value of the vaccine in blood cancer patients who are on treatment that diminishes immune response? What are the risks and benefits of an mRNA vaccine? What does treatment look like in both symptomatic and asymptomatic patients? How are we seeing the Omicron variant affecting this? Tune in to this important discussion today!
Maria Alma Rodriguez, MD, MACP, CMQ, The University of Texas MD Anderson Cancer Center, Houston, TX Recorded on October 21, 2021 In this episode, Dr. Maria Alma Rodriguez from The University of Texas MD Anderson Cancer Center, joins us in discussing the long-term and late effects of cancer treatment, including strategies to support survivors with physical and psychosocial effects. Dr. Rodriguez describes barriers to follow-up care, including why some patients may be lost to this process, challenges to following a cancer survivorship plan, the importance of follow-up care coordination, and how the COVID-19 pandemic has impacted survivorship care. Join us today! This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Pharmacyclics LLC, An AbbVie Company & Janssen Biotech, Inc.
Daniel Verina, DNP, ACNP-BC, Mount Sinai Medical Center, New York, NY Recorded on October 1, 2021 Advanced practice providers, nurses, and other members of the multidisciplinary healthcare team play an important role in treating and supporting newly diagnosed myeloma patients. In this month’s episode, Daniel Verina, DNP, ACNP-BC, Acute Care Nurse Practitioner, Multiple Myeloma Program, at the Mount Sinai Medical Center in New York, shares his perspective into treating newly diagnosed myeloma patients, including how to navigate questions about embarking on the treatment journey, potential side effects, and survival rates. He shares his thoughts on how to best support both the patient and caregiver, navigating discussion surrounding clinical trials, and what challenges lie ahead. Tune in today! This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.
Joshua Richter, MD, Icahn School of Medicine at Mount Sinai, New York, NY Recorded on September 10, 2021 Treating myeloma patients, especially newly diagnosed, can be very complex. How are treatment decisions determined? Who is eligible to receive a transplant? What is the patient’s role in making treatment decisions? In this month’s episode, Dr. Joshua Richter from the Icahn School of Medicine at Mount Sinai Hospital in New York, provides his perspective on treating newly diagnosed myeloma patients, including smoldering myeloma, describes the evolution of CRAB criteria to SLIM CRAB criteria, discusses the importance of quality-of-life considerations, describes how COVID-19 has affected treatment, and reviews exciting myeloma treatment options on the horizon. This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.
Lorenzo Falchi, MD and Leah Szumita, MS, RN, CCRN, ACNS-BC Recorded on August 5, 2021 Clinical trials are the foundation of advancing treatment options. Understanding their importance, dispelling myths and fears about enrollment, and acknowledging disparities in access can help providers educate their patients and discuss treatment in a clinical trial as an option at any point in the patient’s cancer journey. In this episode, we welcome special guest host Leah Szumita, MS, RN, CCRN, ACNS-BC, Director of The Leukemia & Lymphoma Society’s Clinical Trial Support Center as she speaks with Lorenzo Falchi, MD, Assistant Attending, Lymphoma Service, Memorial Sloan-Kettering Cancer Center in New York City, about the importance of clinical trials, understanding patient concerns, barriers to participation and strategies to overcome these barriers, and how clinical trials have been impacted by COVID-19.
David Tate, BSN, RN, PHN, Rio Bravo-Greeley School, Bakersfield, CA Recorded on August 11, 2021 September is Childhood Cancer Awareness Month, a time to recognize the children and families affected by blood cancer. In this month’s special episode, we are joined by David Tate, a registered nurse in the Rio Bravo-Greeley School system in Bakersfield, California to discuss his journey from the father of a cancer survivor to healthcare professional. David shares with us the story of his son’s diagnosis with leukemia at seven months old, how that journey influenced his career in nursing, and how he leans on his experience to help other families navigating this path. Tune in to this heartfelt episode today!
Justine M. Kahn, MD, MS, Columbia University Irving Medical Center, New York, NY Recorded on July 13, 2021 Healthcare disparities are a known factor in cancer care. Understanding these disparities can enable healthcare professionals to more effectively communicate with and treat their patients. In this episode, Dr. Justine Kahn, from the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center in New York City, defines and describes existing healthcare disparities, addresses ways to eliminate disparities, including removing barriers and increasing access to care, underscores the impact of insurance, and discusses the importance of enhancing awareness among primary care providers to reduce challenges that lead to delayed diagnoses. Tune into this important episode for more tips on how providers can eliminate disparities in their practice!
Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on June 18, 2021 Tune in to this very informative and interesting conversation on T-cell lymphoma! Dr. Steven Horwitz, from Memorial Sloan Kettering Cancer Center in New York City, discusses types and diagnostic tests used to identify T-cell lymphoma, goals of treatment, approved and emerging treatment options, including immunotherapy and clinical trials, strategies to manage side effects, including when to stop therapy, and the importance of the multidisciplinary healthcare team.
Jeffrey L. Wolf, MD, University of California San Francisco, San Francisco, CA Recorded on May 27, 2021 In this episode, Dr. Jeffrey Wolf, from the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco, explains what measurable residual disease (MRD) is, how providers can explain the role of MRD to patients, including understanding the tests used, how to counsel patients when there is MRD, where testing is done for patients treated in the community, the way MRD test results will be used in the future, and so much more. Tune in today as Dr. Wolf explores MRD with our moderator, Dr. Ken Miller! This podcast episode is supported by Amgen.
Justin M. Watts, MD, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL Recorded on May 14, 2021 Terminology, available tests, the impact of epigenetics, and the significance of mutations. Understanding the role of genomics in cancer care can be complex. Tune in as Dr. Justin Watts from the Sylvester Comprehensive Cancer Center in Miami, breaks down cancer genomics, discusses the implications of treatment, outlines the various tests available, including their strengths and weaknesses, the importance of educating patients on the meaning of these tests, and the future of genomic testing in hematologic malignancies.
Peter Campbell, PharmD, BCOP, Columbia University Irving Medical Center, New York, NY Recorded on April 23, 2021 The interprofessional oncology team is comprised of many healthcare professionals, each playing an important role in contributing to a patient’s care. Join Dr. Peter Campbell, Clinical Pharmacy Manager from Columbia University Irving Medical Center, as he discusses the vital role of pharmacists on the multidisciplinary team. Dr. Campbell discusses challenges with access to treatment, cost of drugs, and adherence. He reviews many common and novel side effects patients experience, understanding drug-drug interactions, how to determine when to stop treatment, and how to navigate drug shortages. Join this interesting conversation to learn more about exciting drugs coming down the pipeline, how COVID-19 has impacted treatment, and so much more!
Edward A. Stadtmauer, MD, The University of Pennsylvania, Philadelphia, PA Recorded on February 23, 2021 In recognition of March being Myeloma Awareness Month, The Leukemia & Lymphoma Society is pleased to share this informative podcast episode on updates and advancements in multiple myeloma. Healthcare professionals are challenged to stay up-to-date on new and emerging treatments options, including updates in immunotherapy, and to incorporate these treatment approaches into decision making. Dr. Edward Stadtmauer, from The University of Pennsylvania, shares his insights into these topics, as well as discusses myeloma in underserved communities, treatment in the time of the COVID-19 pandemic, and exciting advances in multiple myeloma.
Michael Angarone, DO, FIDSA, Feinberg School of Medicine, Chicago, IL Recorded on February 25, 2021 There are so many questions cancer patients and their families have about the COVID-19 vaccine. What are the differences between the vaccines available? How do they work? Who should get vaccinated? Can one resume activities once vaccinated? This important podcast episodes aims to dispel myths surrounding the COVD-19 vaccine and reiterate its safety for oncology patients, their families, and healthcare professionals. Join our guest, Dr. Michael Angarone of Northwestern University, as he underscores the importance of this vaccine.
Sonali M. Smith, MD, FASCO, The University of Chicago, Chicago, IL Recorded on January 25, 2021 How do we start the conversation? How do we discuss patient expectation and the likelihood of relapse? What role does the timing of relapse play? In this episode, Dr. Sonali Smith, the Elwood V. Jensen Professor of Medicine at The University of Chicago, discusses expectations for disease control and for relapse, the mechanisms of resistance, exciting advances in the treatment of relapsed/refractory lymphoma, including new treatments, and so much more. Tune in to this important talk today! This podcast episode is supported by Epizyme.
Olatoyosi Odenike, MD and Wendy Stock, MD Recorded on January 15, 2021 Join Drs. Wendy Stock and Olatoyosi Odenike from The University of Chicago Medicine, in an important discussion on the progress in the treatment of acute myeloid leukemia, including important updates from the LLS Beat AML Master Trial. Drs. Stock and Odenike talk with Dr. Ken Miller about determining a treatment plan for each patient, the role genetics and epigenetics may play, what the ultimate goals of care are, including having difficult conversations with patients regarding treatment, and monitoring for measurable residual disease and maintenance therapy. Be a part of the conversation today!
Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR Recorded on December 14, 2020 This podcast episode is supported by Epizyme.
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA Recorded on November 19, 2020 This podcast episode is supported by Foundation Medicine, Inc.
Matthew B. Schabath, PhD, Moffitt Cancer Center, Tampa, FL Recorded on November 2, 2020
Gail J. Roboz, MD, Weill Cornell Medical College, New York, NY Recorded on October 2, 2020 This podcast episode is supported by Amgen.
Allison J. Applebaum, Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY Recorded on June 26, 2020
James M. Foran, MD, FRCPC, Mayo Clinic Cancer Center, Jacksonville, FL Recorded on May 28, 2020
Alison Loren, MD, MSCE, Raymond and Ruth Perelman School of Medicine, Philadelphia, PA Recorded on April 21, 2020
Raajit K. Rampal, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY Recorded on March 24, 2020
Tobias M. Hohl, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY Recorded on April 15, 2020
Kerry Cook, PA-C, New York Presbyterian/Columbia University Irving Medical Center, New York, NY Recorded on April 8, 2020
Frederick R. Appelbaum, MD, Fred Hutchinson Cancer Research Center, Seattle, WA Recorded on February 4, 2020
Edith P. Mitchell, MD, MACP, FCPP, Sydney Kimmel Cancer Center at Jefferson, Philadelphia, PA Recorded on January 15, 2020
Jacqueline Casillas, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA Recorded on January 8, 2020
Marybeth Medicke, MSN, RN, El Paso Community College, El Paso, TX Recorded on November 21, 2019
Anita Kumar, MD, Memorial Sloan Kettering Cancer Center, Basking Ridge, NJ Recorded on November 11, 2019
Susan McCall, MSN, ANP-BC, AOCNP®, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on September 18, 2019
Elizabeth A. Weber, BSN, RN, Heather DiFilippo, MSN, CRNP and Erin Medoff, RN, MSN, APRN Recorded live at The Leukemia & Lymphoma Society’s Symposium on CAR T-cell Therapy on June 28, 2019
Frederick L. Locke, MD, Moffitt Cancer Center, Tampa, FL Recorded on September 3, 2019 This podcast episode is supported by Allogene Therapeutics, Inc.
Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center and Gunjan Shah, MD, Memorial Sloan Kettering Cancer Center Recorded live at The Leukemia & Lymphoma Society’s Symposium on CAR T-cell Therapy on June 28, 2019
Dennis Cooper, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ Recorded live at The Leukemia & Lymphoma Society’s Symposium on CAR T-cell Therapy on June 28, 2019
Amy Burd, PhD, Vice President of Research and Strategy, and Alissa Gentile, MSN, RN, Director of the Clinical Trial Support Center at The Leukemia & Lymphoma Society Recorded on May 10, 2019
Brad Zebrack, PhD, MSW, The University of Michigan School of Social Work, Ann Arbor, MI Recorded on March 5, 2019
Richard, MDS survivor since 2016, Nancy, Caregiver, and Vu Duong, MD, University of Maryland School of Medicine, Baltimore, MD Recorded on February 26, 2019
Lewis Silverman, MD, Boston Children’s Hospital, Boston, MA Recorded on February 7, 2019
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA Recorded on December 28, 2018
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA Recorded on December 28, 2018
Alice Mims, MD, MSCR, The James, The Ohio State University Comprehensive Cancer Center, Columbus, OH Recorded on January 10, 2019
Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX Recorded on December 11, 2018